IMDX
Insight Molecular Diagnostics Inc.
There isn't enough reported data to score IMDX yet.
IMDX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
IMDX's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
IMDX PE Valuation
IMDX has no meaningful PE right now: it lost money over the past year.
IMDX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect IMDX's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
IMDX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.52 | +$2.21 |
| Q1 2026 | -$1.51 | +$2.28 |
| Q4 2025 | -$1.65 | +$3.01 |
| Q3 2025 | -$3.09 | +$1.27 |
| Q2 2025 | -$3.73 | +$0.46 |
| Q1 2025 | -$3.79 | +$1.11 |
| Q4 2024 | -$4.66 | -$1.29 |
| Q3 2024 | -$4.36 | +$4.76 |
IMDX is still losing money, but far less than before: $1.52 per share over the past year, against $15.60 at its worst in early 2022.
IMDX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $239K | -54% |
| Q1 2026 | $32K | -99% |
| Q4 2025 | $1.1M | -23% |
| Q3 2025 | $260K | +126% |
| Q2 2025 | $518K | +398% |
| Q1 2025 | $2.1M | +1115% |
| Q4 2024 | $1.5M | +373% |
| Q3 2024 | $115K | -73% |
IMDX's revenue has slid since its 2021 peak: $239,000 last quarter, down 54% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -4771% | -2871 points |
| Q1 2026 | -13791% | -13473 points |
| Q4 2025 | -2058% | +205 points |
| Q3 2025 | -4249% | +7503 points |
| Q2 2025 | -1900% | +2554 points |
| Q1 2025 | -318% | +4947 points |
| Q4 2024 | -2263% | +2890 points |
| Q3 2024 | -11752% | -10234 points |
IMDX's operating margin was −4771% last quarter, down 2871 points from the same quarter a year ago.
IMDX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$10M | -$3.4M |
| Q1 2026 | -$8.3M | -$2.1M |
| Q4 2025 | -$7M | -$1.5M |
| Q3 2025 | -$5.6M | +$86K |
| Q2 2025 | -$6.6M | -$459K |
| Q1 2025 | -$6.2M | -$2.3M |
| Q4 2024 | -$5.6M | -$742K |
| Q4 2023 | -$4.8M | +$5.6M |
IMDX has burned cash in almost every quarter: −$31M over the past year, against −$24M the year before.
IMDX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.5% | +2.2M shares |
| 1 year | +15% | +4.7M shares |
| 3 years | +520% | +30.8M shares |
IMDX has 37M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
IMDX Net Leverage
IMDX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
IMDX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.9 | Oversold |
| Stochastic | 5.8 | Oversold |
IMDX's weekly RSI is 28 (oversold) and its Stochastic is 6 (oversold).
IMDX PE vs Healthcare Sector
IMDX has no meaningful PE right now: it lost money over the past year.
IMDX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.04 | 24% below |
| 20 week MA | $3.96 | 42% below |
| 50 week MA | $4.85 | 52% below |
| 100 week MA | $4.09 | 44% below |
| 200 week MA | $3.95 | 42% below |
IMDX is in a downtrend: it's below all five of its weekly moving averages, and 42% below its 200-week average.
IMDX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $42.4 | $47.0 | +11% |
| 2021 | $47.0 | $46.0 | -2.1% |
| 2022 | $46.0 | $7.60 | -83% |
| 2023 | $7.60 | $2.50 | -67% |
| 2024 | $2.50 | $2.11 | -16% |
| 2025 | $2.11 | $6.37 | +202% |
| 2026 YTD | $6.37 | $2.31 | -64% |
IMDX's yearly returns have swung widely, from +202% in 2025 to −83% in 2022. It's down 64% so far in 2026.